In his first term, President Donald Trump launched a bold and successful initiative against HIV. This time around, the ...

Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

while continuing to reach towards a cure. "Gilead is fueling the next wave of innovation in HIV to help end the epidemic globally," said Jared Baeten, MD, PhD, Senior Vice President, Virology ...

(1 Trusted Source HIV weakens the immune system by attacking infection-fighting cells. While antiretroviral therapy controls the virus, it doesn’t cure it. Mount Sinai researchers ...

Get Instant Summarized Text (Gist) A new strategy using genetically modified natural killer (NK) cells has been developed to target HIV-positive cells. By expressing CD64, these NK cells can hold ...

Biktarvy maintained HIV-1 suppression in 95.4% and HBV suppression in 86.6% of participants after 96 weeks of treatment switch. Lenacapavir with teropavimab and zinlirvimab showed 96% virologic ...

Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy Designation – – Late-Breaker Oral Presentation of Phase 2 Results from the First HIV Cure Clinical Trial Conducted in ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...